vaccin
efficaci
suscept
infect
regardless
symptom
import
endpoint
vaccin
trial
pathogen
high
proport
asymptomat
infect
infect
may
contribut
onward
transmiss
longterm
sequela
congenit
zika
syndrom
howev
estim
resourceintens
aim
identifi
approach
accur
estim
limit
inform
avail
resourc
constrain
model
individu
random
vaccin
trial
gener
network
individu
simul
epidem
diseas
natur
histori
follow
susceptibleexposedinfectioussymptomat
infectiousasymptomat
recov
model
use
approach
estim
also
estim
vaccin
efficaci
progress
symptom
p
correct
rel
risk
intervalcensor
cox
model
accur
estim
requir
serolog
test
particip
cox
model
use
symptomat
infect
return
bias
estim
acquir
serolog
endpoint
sampl
imput
remain
infect
status
yield
unbias
estim
across
valu
basic
reproduct
number
r
accur
estim
p
higher
r
valu
identifi
resourcepreserv
method
accur
estim
p
import
design
trial
diseas
high
proport
asymptomat
infect
asymptomat
infect
epidem
infecti
diseas
interv
censor
model
vaccin
trial
abbrevi
vaccin
efficaci
p
vaccin
efficaci
progress
symptom
vaccin
efficaci
suscept
infect
world
health
organ
identifi
list
prioriti
pathogen
potenti
caus
futur
public
health
emerg
intern
concern
coalit
epidem
prepared
innov
commit
billion
dollar
vaccin
develop
effort
start
pathogen
middl
east
respiratori
syndrom
coronaviru
lassa
viru
nipah
viru
pathogen
well
other
world
health
organ
list
zika
viru
high
proport
asymptomat
mild
infect
vaccin
efficaci
suscept
infect
regardless
symptom
level
import
endpoint
vaccin
trial
pathogen
infect
may
contribut
onward
transmiss
outcom
congenit
zika
syndrom
even
without
primari
symptom
howev
estim
resourceintens
sinc
requir
test
trial
particip
either
period
conduct
assay
infect
throughout
trial
perform
serolog
test
trial
conclus
natur
vaccinederiv
immun
respons
distinguish
test
trial
particip
also
necessari
estim
vaccin
efficaci
progress
symptom
p
anoth
critic
outcom
measur
rodriguezbarraqu
et
al
note
analysi
dengu
vaccin
trial
result
protect
symptomat
infect
may
differ
protect
infect
case
dengu
p
may
neg
antibodydepend
enhanc
gener
therefor
import
consid
estim
p
analyz
trial
result
aim
identifi
method
accur
estim
p
limit
amount
inform
avail
resourcesboth
time
moneyar
constrain
throughout
paper
use
asymptomat
synonym
subclin
mean
infect
episod
gener
suffici
symptom
prompt
test
would
reveal
particip
current
infect
caus
pathogen
method
model
vaccin
trial
first
gener
model
main
popul
network
individu
group
commun
structur
describ
previous
see
web
tabl
avail
http
academicoup
comaj
paramet
model
compartment
use
determinist
differenti
equat
dynam
main
popul
stochast
dynam
commun
simul
epidem
main
popul
season
transmiss
rate
gener
epidem
curv
shape
similar
epidem
curv
zika
viru
outbreak
brazil
diseas
introduc
commun
via
infecti
contact
main
popul
transmiss
occur
infect
person
transmit
viru
suscept
contact
commun
suscept
person
daili
probabl
infect
infecti
contact
e
forc
infect
well
daili
extern
hazard
infect
main
popul
vari
preval
main
popul
diseas
natur
histori
follow
susceptibleexposedinfectioussymptomat
infectiousasymptomat
recov
model
estim
incub
infecti
period
zikalik
diseas
web
tabl
vector
transmiss
directli
model
serial
interv
simul
diseas
shorter
zika
viru
diseas
symptomat
asymptomat
infect
assum
equal
infecti
whether
person
infect
symptomat
individu
asymptomat
individu
affect
probabl
becom
symptomat
baselin
paramet
model
assum
infect
vaccin
control
group
becom
symptomat
base
estim
proport
zika
viru
infect
symptomat
epidem
vaccin
trial
simul
network
individu
group
rel
disconnect
commun
network
individu
larg
commun
trial
peopl
commun
enrol
individu
random
vaccin
group
control
group
person
enrol
trial
assum
naiv
infect
practic
might
requir
serolog
test
individu
prior
enrol
vaccin
imperfect
leaki
mean
reduc
elimin
probabl
infect
upon
exposur
infecti
person
daili
probabl
infect
vaccine
infecti
contact
e
assum
direct
vaccin
efficaci
estim
mean
differ
approach
describ
tabl
trial
statu
ie
vaccin
control
explanatori
variabl
cox
proport
hazard
model
person
never
infect
censor
end
trial
approach
assum
time
infect
known
exactli
day
even
asymptomat
infect
therefor
would
strictli
applic
frequent
test
perform
throughout
trial
approach
assum
infect
unobserv
asymptomat
infect
symptomat
infect
includ
cox
regress
person
infect
asymptomat
assum
surviv
without
infect
end
followup
latter
approach
lead
bia
estim
see
figur
result
section
consid
addit
approach
approach
use
risk
ratio
infect
measur
end
trial
rather
hazard
ratioan
approach
known
bias
use
leaki
vaccin
approach
correct
rel
risk
estim
assumpt
recov
ratio
cumul
hazard
approach
use
intervalcensor
model
exact
day
infect
symptomat
individu
known
practic
would
laboratoryconfirm
asymptomat
infect
individu
interv
day
infect
rang
day
person
last
neg
serolog
test
day
first
posit
serolog
test
two
differ
interv
length
assess
determin
whether
increas
frequenc
test
yield
precis
result
mention
approach
assum
abil
serolog
test
distinguish
vaccineacquir
immun
natur
acquir
immun
current
possibl
vaccinespathogen
final
approach
sampl
trial
particip
test
infect
status
asymptomat
individu
sampl
imput
intervalcensor
model
approach
use
imput
data
set
result
network
commun
analyz
first
approach
treat
commun
larg
commun
altern
account
potenti
heterogen
hazard
rate
commun
cox
model
approach
stratifi
commun
estim
approach
calcul
separ
within
commun
metaanalyz
use
inversevari
weight
empir
coverag
probabl
calcul
proport
simul
confid
interv
cover
true
paramet
model
statist
power
estim
proport
simul
p
less
use
wald
test
null
hypothesi
estim
greater
trial
also
simul
fewer
particip
assess
power
smaller
trial
addit
evalu
efficaci
vaccin
prevent
progress
symptom
p
estim
infect
control
final
assess
whether
result
hold
context
trial
paramet
trial
length
r
proport
infect
individu
arm
trial
becom
symptomat
vari
r
code
r
foundat
statist
comput
vienna
austria
analys
avail
github
figur
display
result
median
simul
singlecommun
network
show
estim
approach
describ
across
valu
r
basic
reproduct
number
expect
approach
return
accur
estim
approach
return
estim
bias
toward
null
differenti
overestim
persontim
risk
wors
overestim
control
figur
bia
exacerb
r
increas
approach
return
estim
bias
toward
null
comparison
true
valu
also
expect
also
worsen
higher
level
r
approach
correct
bia
convert
riskbas
analysi
ratebas
analysi
intervalcensor
cox
proport
hazard
model
approach
return
estim
approxim
equal
input
model
approach
requir
fewer
unknown
baselin
hazard
vector
coeffici
covari
ie
trial
statu
commun
stratifi
time
event
nonev
infin
unknown
baselin
hazard
vector
coeffici
covari
ie
trial
statu
commun
stratifi
time
event
nonev
asymptomat
event
infin
rel
risk
estim
ascertain
prospect
total
count
end
trial
ascertain
end
trial
unknown
baselin
hazard
vector
coeffici
covari
ie
trial
statu
commun
stratifi
time
event
nonev
infin
asymptomat
event
treat
interv
resourc
would
necessit
cox
model
perfect
knowledg
infect
time
approach
use
serolog
test
serolog
test
respect
rather
frequent
monitor
infect
throughout
followup
period
approach
intervalcensor
cox
model
test
end
trial
yield
result
approach
test
time
without
substanti
differ
coverag
probabl
power
set
consid
tabl
figur
thu
approach
approach
yield
accur
estim
test
requir
end
trial
even
singl
serolog
test
could
resourceintens
approach
requir
test
trial
particip
end
trial
result
accur
estim
figur
valu
r
consid
accur
estim
p
tabl
r
valu
test
trial
particip
end
trial
substanti
reduc
requir
resourc
howev
number
case
low
web
tabl
sampl
accur
estim
p
approach
larger
varianc
other
baselin
paramet
ie
wider
confid
interv
see
web
tabl
larger
sampl
sampl
accur
estim
null
p
tabl
combin
approach
perform
similarli
approach
consist
similar
perform
approach
similar
result
obtain
analys
commun
figur
howev
number
case
low
r
metaanalys
approach
imprecis
result
essenti
unchang
across
simul
longer
durat
trial
ebolalik
paramet
web
tabl
chang
differ
proport
symptomat
person
among
vaccin
control
group
ie
p
shown
web
figur
web
tabl
vaccin
effect
suscept
infect
progress
symptom
serolog
test
help
differenti
figur
differenti
misclassif
atrisk
persontim
panel
show
realitywho
truli
infect
truli
still
risk
panel
b
show
perceiv
infect
still
risk
consid
symptomat
individu
consid
symptomat
event
presum
persontim
risk
increas
vaccin
group
control
group
person
asymptomat
infect
perceiv
uninfect
risk
entir
period
trial
vaccin
group
peopl
perceiv
still
risk
panel
b
realiti
remain
risk
panel
sinc
peopl
asymptomat
infect
control
group
peopl
perceiv
risk
panel
b
realiti
remain
risk
panel
peopl
infect
therefor
peopl
incorrectli
still
perceiv
risk
control
group
vaccin
group
appar
incid
underestim
control
vaccin
group
lead
bia
toward
null
bia
exacerb
r
increas
peopl
control
group
becom
infect
still
perceiv
risk
time
postrandom
persontim
risk
control
overestim
factor
e
p
p
rel
vaccin
group
cumul
hazard
time
p
symptomat
proport
control
p
efficaci
vaccin
infect
efficaci
vaccin
diseas
given
infect
respect
greater
nonneg
p
posit
p
vaccin
efficaci
progress
symptom
vaccin
efficaci
suscept
infect
abbrevi
cov
coverag
vaccin
efficaci
suscept
infect
empir
coverag
probabl
calcul
use
proport
simul
confid
interv
cover
true
paramet
model
b
imput
sampl
result
empir
coverag
probabl
imput
sampl
result
empir
coverag
probabl
p
except
total
number
case
low
similar
result
also
obtain
simul
higher
r
valu
eg
web
tabl
web
figur
howev
approach
less
precis
although
coverag
r
number
peopl
elig
trial
ie
remain
uninfect
trial
begin
much
lower
due
high
rate
infect
decreas
size
sampl
use
imput
pathogen
high
proport
mild
asymptomat
infect
understand
whether
vaccin
prevent
infect
sole
symptomat
infect
well
understand
vaccin
effect
progress
symptom
critic
determin
epidemiolog
impact
vaccin
howev
cost
resourc
pose
major
barrier
estim
import
valu
discuss
differ
approach
vari
level
accuraci
resourc
requir
estim
p
correct
rel
risk
estim
approach
intervalcensor
cox
model
approach
imput
intervalcensor
cox
model
approach
provid
estim
close
input
model
across
valu
r
cours
also
obtain
assumpt
perfect
knowledg
time
asymptomat
infect
approach
cox
model
consid
symptomat
infect
prove
bias
especi
higher
valu
r
approach
return
accur
estim
p
except
approach
r
low
due
small
number
case
overal
sampl
case
higher
coverag
desir
larger
sampl
percentag
use
tabl
simul
parameter
zikalik
pathogen
given
high
proport
asymptomat
zika
infect
result
simul
ebolalik
paramet
show
method
applic
pathogen
zika
viru
web
figur
practic
use
cox
proport
hazard
model
time
infect
would
entail
test
everyon
frequent
perhap
weekli
even
daili
infect
throughout
trial
requir
substanti
expenditur
money
time
use
correct
rel
risk
estim
intervalcensor
cox
model
accur
estim
p
obtain
serolog
test
end
trial
test
trial
popul
imput
event
statu
remain
asymptomat
trial
particip
substanti
reduc
resourc
need
still
provid
critic
inform
vaccin
approach
work
trial
conduct
larg
commun
trial
conduct
disconnect
commun
recent
malaria
trial
trial
commun
increas
heterogen
bia
heterogen
hazard
rate
probabl
pronounc
method
account
heterogen
stratif
metaanalys
incorpor
random
effect
therefor
use
although
number
case
low
approach
may
imprecis
mani
simplifi
assumpt
made
model
includ
complet
ascertain
infecti
case
perfect
sensit
specif
diagnost
test
compar
infect
vaccine
infect
control
estim
p
approach
requir
substanti
fewer
resourc
estim
p
approach
accur
approach
particip
must
test
begin
trial
ensur
expos
immun
includ
person
preexist
immun
trial
would
reduc
total
number
overal
case
thu
power
limit
abil
draw
statist
signific
conclus
vaccin
effect
challeng
howev
limit
diseas
high
proport
mild
asymptomat
infect
sinc
prior
immun
would
reduc
power
trial
addit
distinguish
natur
vaccinederiv
immun
challeng
especi
begin
outbreak
emerg
infecti
diseas
much
known
serolog
test
like
earli
stage
develop
therefor
invest
diagnost
develop
also
critic
ensur
accur
estim
identifi
method
accur
estim
p
requir
serolog
test
trial
particip
end
trial
acquir
serolog
endpoint
sampl
yield
unbias
estim
substanti
reduc
requir
resourc
parameter
zikalik
diseas
approach
exact
paramet
describ
meant
repres
particular
epidem
context
mere
serv
guid
think
accur
estim
import
endpoint
vaccin
trial
differ
set
limit
resourc
inform
r
code
simpl
model
readili
modifi
reflect
diseas
vaccin
settingspecif
paramet
identifi
resourcepreserv
method
import
design
trial
diseas
high
proport
asymptomat
mild
infect
especi
case
still
infecti
understand
potenti
sourc
bia
differ
approach
allow
accur
estim
epidem
set
